Literature DB >> 21478156

Myotubularin regulates Akt-dependent survival signaling via phosphatidylinositol 3-phosphate.

Gina L Razidlo1, Dawn Katafiasz, Gregory S Taylor.   

Abstract

Myotubularin is a 3-phosphoinositide phosphatase that is mutated in X-linked myotubular myopathy, a severe neonatal disorder in which skeletal muscle development and/or regeneration is impaired. In this report we provide evidence that siRNA-mediated silencing of myotubularin expression markedly inhibits growth factor-stimulated Akt phosphorylation, leading to activation of caspase-dependent pro-apoptotic signaling in HeLa cells and primary human skeletal muscle myotubes. Myotubularin silencing also inhibits Akt-dependent signaling through the mammalian target of rapamycin complex 1 as assessed by p70 S6-kinase and 4E-BP1 phosphorylation. Similarly, phosphorylation of FoxO transcription factors is also significantly reduced in myotubularin-deficient cells. Our data further suggest that inhibition of Akt activation and downstream survival signaling in myotubularin-deficient cells is caused by accumulation of the MTMR substrate lipid phosphatidylinositol 3-phosphate generated from the type II phosphatidylinositol 3-kinase PIK3C2B. Our findings are significant because they suggest that myotubularin regulates Akt activation via a cellular pool of phosphatidylinositol 3-phosphate that is distinct from that generated by the type III phosphatidylinositol 3-kinase hVps34. Because impaired Akt signaling has been tightly linked to skeletal muscle atrophy, we hypothesize that loss of Akt-dependent growth/survival cues due to impaired myotubularin function may be a critical factor underlying the severe skeletal muscle atrophy characteristic of muscle fibers in patients with X-linked myotubular myopathy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21478156      PMCID: PMC3103374          DOI: 10.1074/jbc.M110.197749

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.

Authors:  S Ramaswamy; N Nakamura; F Vazquez; D B Batt; S Perera; T M Roberts; W R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  Myotubular myopathy. Persistence of fetal muscle in an adolescent boy.

Authors:  A J Spiro; G M Shy; N K Gonatas
Journal:  Arch Neurol       Date:  1966-01

3.  Familial "myotubular" myopathy.

Authors:  G K van Wijngaarden; P Fleury; J Bethlem; A E Meijer
Journal:  Neurology       Date:  1969-09       Impact factor: 9.910

4.  Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors:  D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

5.  Production of phosphatidylinositol 5-phosphate by the phosphoinositide 3-phosphatase myotubularin in mammalian cells.

Authors:  Hélène Tronchère; Jocelyn Laporte; Caroline Pendaries; Claire Chaussade; Laurence Liaubet; Luciano Pirola; Jean-Louis Mandel; Bernard Payrastre
Journal:  J Biol Chem       Date:  2003-12-01       Impact factor: 5.157

6.  Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.

Authors:  Marco Sandri; Claudia Sandri; Alex Gilbert; Carsten Skurk; Elisa Calabria; Anne Picard; Kenneth Walsh; Stefano Schiaffino; Stewart H Lecker; Alfred L Goldberg
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

7.  MTMR9 increases MTMR6 enzyme activity, stability, and role in apoptosis.

Authors:  Jun Zou; Shao-Chun Chang; Jasna Marjanovic; Philip W Majerus
Journal:  J Biol Chem       Date:  2008-11-27       Impact factor: 5.157

8.  The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice.

Authors:  Anna Buj-Bello; Vincent Laugel; Nadia Messaddeq; Hala Zahreddine; Jocelyn Laporte; Jean-Francois Pellissier; Jean-Louis Mandel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

Review 9.  The control of cell mass and replication. The DNA unit--a personal 20-year study.

Authors:  D B Cheek
Journal:  Early Hum Dev       Date:  1985-12       Impact factor: 2.079

10.  Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma.

Authors:  H Azzedine; A Bolino; T Taïeb; N Birouk; M Di Duca; A Bouhouche; S Benamou; A Mrabet; T Hammadouche; T Chkili; R Gouider; R Ravazzolo; A Brice; J Laporte; E LeGuern
Journal:  Am J Hum Genet       Date:  2003-04-08       Impact factor: 11.025

View more
  18 in total

1.  Plentiful PtdIns5P from scanty PtdIns(3,5)P2 or from ample PtdIns? PIKfyve-dependent models: Evidence and speculation (response to: DOI 10.1002/bies.201300012).

Authors:  Assia Shisheva; Diego Sbrissa; Ognian Ikonomov
Journal:  Bioessays       Date:  2014-11-18       Impact factor: 4.345

2.  The CMT4B disease-causing phosphatases Mtmr2 and Mtmr13 localize to the Schwann cell cytoplasm and endomembrane compartments, where they depend upon each other to achieve wild-type levels of protein expression.

Authors:  Aubree A Ng; Anne M Logan; Eric J Schmidt; Fred L Robinson
Journal:  Hum Mol Genet       Date:  2013-01-07       Impact factor: 6.150

Review 3.  Pathophysiological concepts in the congenital myopathies: blurring the boundaries, sharpening the focus.

Authors:  Gianina Ravenscroft; Nigel G Laing; Carsten G Bönnemann
Journal:  Brain       Date:  2014-12-31       Impact factor: 13.501

4.  Myotubularin-deficient myoblasts display increased apoptosis, delayed proliferation, and poor cell engraftment.

Authors:  Michael W Lawlor; Matthew S Alexander; Marissa G Viola; Hui Meng; Romain Joubert; Vandana Gupta; Norio Motohashi; Richard A Manfready; Cynthia P Hsu; Ping Huang; Anna Buj-Bello; Louis M Kunkel; Alan H Beggs; Emanuela Gussoni
Journal:  Am J Pathol       Date:  2012-07-27       Impact factor: 4.307

5.  Differential muscle hypertrophy is associated with satellite cell numbers and Akt pathway activation following activin type IIB receptor inhibition in Mtm1 p.R69C mice.

Authors:  Michael W Lawlor; Marissa G Viola; Hui Meng; Rachel V Edelstein; Fujun Liu; Ke Yan; Elizabeth J Luna; Alexandra Lerch-Gaggl; Raymond G Hoffmann; Christopher R Pierson; Anna Buj-Bello; Jennifer L Lachey; Scott Pearsall; Lin Yang; Cecilia J Hillard; Alan H Beggs
Journal:  Am J Pathol       Date:  2014-04-13       Impact factor: 4.307

6.  PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models.

Authors:  Nesrin Sabha; Jonathan R Volpatti; Hernan Gonorazky; Aaron Reifler; Ann E Davidson; Xingli Li; Nadine M Eltayeb; Claudia Dall'Armi; Gilbert Di Paolo; Susan V Brooks; Ana Buj-Bello; Eva L Feldman; James J Dowling
Journal:  J Clin Invest       Date:  2016-08-22       Impact factor: 14.808

Review 7.  PtdIns5P: news and views of its appearance, disappearance and deeds.

Authors:  Assia Shisheva
Journal:  Arch Biochem Biophys       Date:  2013-08-02       Impact factor: 4.013

Review 8.  Phosphatidylinositol 3-phosphates-at the interface between cell signalling and membrane traffic.

Authors:  Andrea L Marat; Volker Haucke
Journal:  EMBO J       Date:  2016-02-17       Impact factor: 11.598

9.  Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy.

Authors:  Michael W Lawlor; Dustin Armstrong; Marissa G Viola; Jeffrey J Widrick; Hui Meng; Robert W Grange; Martin K Childers; Cynthia P Hsu; Michael O'Callaghan; Christopher R Pierson; Anna Buj-Bello; Alan H Beggs
Journal:  Hum Mol Genet       Date:  2013-01-09       Impact factor: 6.150

10.  MiR-506-3p suppresses the proliferation of ovarian cancer cells by negatively regulating the expression of MTMR6.

Authors:  Yuan Wang; Xia Lei; Chengying Gao; Yanxia Xue; Xiaolin Li; Haiying Wang; Yan Feng
Journal:  J Biosci       Date:  2019-12       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.